Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
BeOne Medicines
Arcus Biosciences, Inc.
Tizona Therapeutics, Inc
Canadian Cancer Trials Group
Eli Lilly and Company
City of Hope Medical Center
Eli Lilly and Company
Innate Pharma
Novartis
OncoNano Medicine, Inc.
NeoTX Therapeutics Ltd.
Bolt Biotherapeutics, Inc.
National Cancer Institute (NCI)
Nanobiotix
Rondo Therapeutics
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Nurix Therapeutics, Inc.
Exelixis
Xencor, Inc.
Numab Therapeutics AG
Incyte Corporation
Genentech, Inc.
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Theratechnologies
Seagen Inc.
Sotio Biotech Inc.
Novartis
Zumutor Biologics Inc.
AstraZeneca
Xencor, Inc.
ADC Therapeutics S.A.
Pliant Therapeutics, Inc.
Eli Lilly and Company
Ikena Oncology
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
QuantumLeap Healthcare Collaborative
Fate Therapeutics
Fate Therapeutics
Tempest Therapeutics
Xencor, Inc.
Evelo Biosciences, Inc.
Mabpro, a.s.